Texas H&S §481.116 Possession of Controlled Substance Penalty Group 2

Statutory elements — § 481.116(a)

Texas Health & Safety Code § 481.116(a) provides that, except as authorized by Chapter 481, a person commits an offense if the person knowingly or intentionally possesses a controlled substance listed in Penalty Group 2, unless the person obtained the substance directly from or under a valid prescription or order of a practitioner acting in the course of professional practice.

"Knowingly or intentionally" mens rea. Under Penal Code § 6.03(a)-(b), the defendant must either intend to possess the substance or know that the substance is in their possession. The defendant must know the substance is a controlled substance though identification of the specific substance is not required.

"Possesses." Penal Code § 1.07(a)(39) defines possession as actual care, custody, control, or management. Both actual and constructive possession are reachable; constructive possession requires "affirmative links" connecting the defendant to the location and contents of the substance.

"Controlled substance" and Penalty Group 2. § 481.002(5) defines controlled substance to include adulterants and dilutants. § 481.103 lists the Penalty Group 2 substances — primarily hallucinogenic and stimulant substances including MDMA and its analogs, mescaline (excluding peyote), psilocybin, psilocin, certain synthetic stimulants, and additional substances added by amendment in successive legislative sessions.

Prescription exception. Substances obtained directly from or under a valid prescription from a practitioner acting in the course of professional practice are excluded. Few PG 2 substances are routinely prescribed, but legitimate research and clinical-trial contexts have produced occasional defense applications.

Affirmative defenses. § 481.062 provides limited registration and exception defenses for certain authorized handlers (researchers, manufacturers, distributors). The affirmative defense applies only when the handler operates within the scope of registration; recreational diversion is not covered.

What is in Penalty Group 2

Penalty Group 2 under § 481.103 is concentrated on hallucinogenic substances and certain stimulants. The list has grown substantially since 1973 as the legislature has added newly-discovered substances and "analog" provisions to capture chemically-modified versions of regulated substances.

The substances that drive prosecution volume. MDMA (commonly called ecstasy or "molly"), psilocybin and psilocin (psychedelic mushrooms), mescaline (excluding peyote which is regulated separately), and certain MDMA analogs generate most § 481.116 prosecutions. The synthetic substances 2C-B, 2C-I, and various other "research chemicals" appear in PG 2 listings or are reached through the analog provisions.

The analog substance reach. § 481.106 establishes a "controlled substance analog" framework — a substance the chemical structure of which is substantially similar to a controlled substance, and which has stimulant, depressant, or hallucinogenic effect substantially similar to that of a controlled substance. The analog provision allows prosecution of newly-developed substances before they are individually scheduled. Defense framing in analog cases requires expert chemistry testimony about structural similarity and pharmacological effect.

Mescaline and the peyote distinction. Mescaline is in Penalty Group 2; peyote is regulated separately. § 481.111(a) provides exceptions for members of the Native American Church for ceremonial peyote use under specific circumstances. The mescaline-versus-peyote distinction is fact-specific and worth verifying in every case where botanical peyote material is involved.

Psilocybin in Texas — note on the modern landscape. Texas has not joined the small number of states that have decriminalized or expanded research access to psilocybin. Texas House Bill 1802 (passed in 2021) authorized state-supported research into psilocybin for treatment of certain conditions in veterans, but recreational possession remains a § 481.116 offense.

PG 2 vs. PG 2-A. Synthetic cannabinoids (K2, Spice, and analogs) are not in Penalty Group 2 — they are in Penalty Group 2-A under § 481.1031, with prosecution under § 481.1161. The carve-out is consequential and discussed in the next section.

PG 2 weight tiers — and the difference from PG 1

The penalty for § 481.116 turns on the aggregate weight of the substance under the same aggregation rule applied to PG 1 prosecutions. § 481.116(b)-(e) sets four weight tiers — one fewer than PG 1:

§ 481.116(b) — Less than 1 gram. State jail felony under Penal Code § 12.35. Punishment range: 180 days to 2 years in state jail plus a fine up to $10,000. State jail felonies are served day-for-day without good-conduct credit.

§ 481.116(c) — 1 gram or more but less than 4 grams. Third-degree felony under § 12.34. Punishment range: 2 to 10 years TDCJ plus a fine up to $10,000.

§ 481.116(d) — 4 grams or more but less than 400 grams. Second-degree felony under § 12.33. Punishment range: 2 to 20 years TDCJ plus a fine up to $10,000.

§ 481.116(e) — 400 grams or more. First-degree felony with enhanced configuration. Punishment range: 5 to 99 years or life TDCJ plus a fine up to $50,000.

The key difference from PG 1. PG 2 collapses the 4-200-gram and 200-400-gram bands into a single 4-400-gram second-degree tier. PG 1 separates them, giving prosecutors a first-degree-felony option at 200 grams. The practical effect: PG 2 cases with quantities between 200 and 400 grams are charged as second-degree felonies rather than first-degree felonies — a meaningful reduction in maximum exposure for that quantity band.

Aggregation under § 481.002(5). The aggregation rule applies identically to PG 1 and PG 2. MDMA pills cut with binders, MDMA in liquid solution, mescaline-containing tea, psilocybin mushrooms (where the mushroom matter itself counts toward weight) — all are weighed at total mixture weight. Mushrooms in particular present substantial aggregation exposure because the mushroom material is a substantial percentage of the prosecution weight, while pure psilocybin content is a small fraction.

Drug-free zone enhancement under § 481.134. The zone enhancement applies to § 481.116 offenses on the same terms as PG 1 offenses — moving the offense up one penalty level and triggering additional minimum confinement requirements in certain configurations.

PG 2 vs. PG 2-A — the synthetic cannabinoid carve-out

In 2015 the Texas legislature carved synthetic cannabinoids out of Penalty Group 2 and into a parallel Penalty Group 2-A under § 481.1031, with prosecution under § 481.1161. The carve-out was a legislative response to the proliferation of K2 / Spice products marketed in convenience stores as "potpourri" or "incense" but designed to produce a cannabis-like effect when smoked or vaped.

§ 481.1031 scope. PG 2-A covers synthetic cannabinoids — a broad chemical class including JWH-018, JWH-073, AM-2201, and the many subsequent generations of synthetic cannabinoid molecules designed to circumvent prior listings. The legislature added "structural analog" coverage to capture newly-developed substances without waiting for individual scheduling.

§ 481.1161 penalties. The PG 2-A penalty structure parallels but does not duplicate the PG 2 structure. Under 2 ounces is Class B misdemeanor; 2-4 ounces is Class A; 4 ounces or more is state jail felony or higher depending on weight. The lower-tier configurations are significantly less severe than PG 2 — a 2-ounce possession case is a Class B misdemeanor rather than a felony.

Identification challenges in synthetic substance cases. The principal defense issue is whether the seized substance is in fact a scheduled synthetic cannabinoid (PG 2-A) or a non-scheduled analog substance. Many newer synthetic cannabinoids appear in markets before the legislature can add them to the schedule. Defense counsel should examine the chemical composition disclosed in the lab report and verify that the identified substance is actually within the scheduled chemical structure under § 481.1031.

The "designer drug" charging problem. Where law enforcement seizes an unidentified substance from a synthetic-substance market, the state may attempt to prosecute under PG 2 (as an analog of a PG 2 hallucinogen), under PG 2-A (as a synthetic cannabinoid or analog), or under § 481.106 (as a controlled-substance analog of any scheduled drug). Each charging pathway has different elements; defense counsel should examine which pathway the indictment uses and challenge the substance-identification accordingly.

Why the distinction matters for charging strategy. A defendant facing a synthetic substance prosecution often has a meaningful charge-reduction path if the substance is properly characterized as PG 2-A rather than PG 2. Defense counsel should not accept the original charging pathway without verifying it against the substance actually identified by the laboratory.

How these cases actually arise

Texas § 481.116 prosecutions cluster around several recognizable case patterns.

Music festival and event-venue prosecutions. MDMA prosecutions concentrate at large-scale music events — electronic dance music festivals, concert tours, multi-day camping events. Law enforcement deploys uniformed and undercover officers, K-9 units at entrance points, and partnership operations with private venue security. Possession arrests at these events often involve user-quantity amounts (state jail felony) and produce significant volume.

College campus and party-house prosecutions. MDMA and psilocybin prosecutions cluster around college towns and party-house locations. Investigations frequently begin from medical-emergency call-outs (suspected overdose, intoxication) that produce evidence of possession on responding paramedics and officers.

Online marketplace cases. Increasingly common. Substances purchased through dark-web marketplaces (Silk Road successors, encrypted marketplace successors) are shipped through the mail. Postal inspectors and Drug Enforcement Administration agents intercept packages; controlled deliveries to the recipient produce arrests. Substances commonly intercepted include MDMA in pill or powder form, psilocybin in mushroom or capsule form, and the various 2C-series substances.

Tour bus and travel-related stops. Concert tour buses, road-trip vehicles to festivals, and vehicles transiting interstate highways are frequent locations of PG 2 substance discoveries. Fourth Amendment posture on the vehicle stop dominates the defense.

Therapy-adjacent and "underground" use cases. A small but growing category. Defendants charged with PG 2 substance possession in contexts where the substance was used for self-treatment of mental health conditions, integration-therapy contexts, or other psychedelic-research-adjacent activity. These cases sometimes present unique mitigation profiles but the substantive law is unchanged.

Mushroom-cultivation cases. Cultivation of psilocybin mushrooms in residential settings is increasingly common. Cultivation cases produce both possession charges and sometimes § 481.112 manufacture charges. The aggregation rule applies to the cultivated material — fresh mushroom material is weighed at fresh weight, dried at dried weight, producing very different penalty exposures.

Mail-order chemical research substance cases. Some defendants order chemicals labeled "not for human consumption" or marketed as research compounds. The label does not preclude prosecution; the substance identification controls.

Defense strategy — identification, possession, suppression

The defense template for § 481.116 cases parallels the PG 1 framework but with PG 2-specific dimensions.

Fourth Amendment suppression. Same framework as PG 1. Festival arrests at controlled entry points raise specific consent and search-condition issues. Online-purchase cases raise issues about the legality of mail interception, the controlled-delivery doctrine, and the scope of post-delivery searches. K-9 alerts and the reliability of the alerting dog remain a productive defense focus.

Substance identification. The state must prove the substance is in fact a PG 2 controlled substance. Identification is established through DPS lab testing — GC-MS for confirmation. PG 2 substances are sometimes harder to identify than PG 1 substances because of the diversity of analog molecules; lab capacity and method coverage matter. Defense counsel should review the lab report carefully and challenge any identification that depends on presumptive testing alone or on inadequate method validation.

The "analog" challenge. Where the substance is charged under the analog framework (§ 481.106), the state must prove both structural similarity to a scheduled substance and pharmacological effect substantially similar to that of a scheduled substance. Both elements require expert evidence. Defense chemistry experts can sometimes disrupt the structural-similarity testimony; defense pharmacology experts can sometimes disrupt the pharmacological-effect testimony. Analog prosecutions are meaningfully more defensible than direct-listing prosecutions.

Possession element — actual vs. constructive. Standard affirmative-links framework. Festival cases often involve shared spaces (campsites, group tents, vehicle interiors) and multi-occupant situations that present genuine constructive-possession issues.

Weight challenges. Mushroom cases present distinct weight issues — fresh-weight versus dried-weight versus extract weight. The state's methodology and the actual material weighed are reviewable. MDMA pill cases present aggregation issues about binders, fillers, and coatings; pure-MDMA content versus pill weight can produce meaningful tier differences.

PG 2 vs. PG 2-A characterization. Where the substance can be characterized as PG 2-A rather than PG 2, the misdemeanor versus felony charging difference is dramatic. Defense counsel should verify the charging classification against the laboratory identification and the schedule.

Pretrial diversion and Drug Court. Most Texas counties make first-offense user-quantity PG 2 cases eligible for diversion programs. The diversion track avoids felony conviction and the substantial collateral consequences of a controlled-substance record.

First 30 days — what to do, in order

Days 1–3. Retain counsel before any further interview. PG 2 cases frequently involve festival or event arrests with rapid charging timelines and limited bond evidence. Counsel arranges pretrial release and instructs the defendant on no-contact, no-statement, and conditional-release obligations. The defendant should not discuss the case on recorded jail calls or with anyone besides counsel.

Days 3–10. Counsel issues preservation letters to the festival or event operator (entrance and security CCTV), the law enforcement agency that arrested (body cameras, dashcams, K-9 deployment records), and any third-party witnesses whose contact information is available. For online-purchase cases, counsel issues preservation letters to the relevant postal authorities and any cloud-account providers that may hold communications evidence.

Days 10–20. Counsel requests the offense report, search-warrant affidavit (where applicable), K-9 deployment record, and the laboratory analysis report (or estimated completion date). Counsel identifies the suppression issues, the substance-identification questions, and the affirmative-links posture. For analog or borderline-schedule substances, counsel begins the chemistry/pharmacology expert search.

Days 20–30. Counsel opens dialogue with the prosecutor on charging configuration, diversion eligibility, and plea posture. For first-offense state-jail and third-degree configurations, pretrial diversion or Drug Court is often the operative defense goal. For analog or contested-identification cases, defense counsel evaluates the substance-identification challenge before committing to a plea track. Where the substance can be characterized as PG 2-A rather than PG 2, the misdemeanor reclassification is the most consequential negotiation in the case.